SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market participants are actively debating the legitimacy of recent after-hours announcements regarding a pause in geopolitical tensions, with many community members labeling the recurring price swings as deliberate market manipulation by political leadership. The consensus among traders reflects deep frustration with extreme volatility and the perceived disconnect between policy rhetoric and actual market outcomes, leading to a climate of heightened skepticism toward short-term news-driven rallies.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing sharp downward pressure as community members react to unfavorable legal rulings concerning platform safety and addictive design, sparking heated debates over whether this creates a buying opportunity or signals long-term regulatory risk. While some investors view the sell-off as an overreaction to manageable legal costs, others are bracing for further volatility amid broader market concerns over AI spending, potential war, and the precedent these cases set for the entire social media sector.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The market is experiencing significant volatility and downward pressure as investors grow increasingly skeptical of Trump's diplomatic claims regarding the Iran conflict, with many in the community labeling his statements as market manipulation. Traders are actively debating whether to buy the dip or prepare for a deeper bear market, as sentiment shifts toward the belief that tweets no longer carry their previous weight in steering market direction.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the public react to the company's volatile stock performance and President Trump's shifting deadlines regarding ongoing tensions in the Middle East. The online discourse is heavily polarized, with critics pointing to the company's financial losses and market manipulation concerns, while supporters continue to defend the administration's strategic approach to the conflict.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing intense volatility and bearish sentiment as investors weigh the competitive threat of new AI models against the company's efforts to grow its advertising segment and streamline operations. Community discussion is heavily divided between those viewing the stock as a deeply undervalued long-term opportunity and others concerned that AI could fundamentally disrupt the company's traditional game engine model.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as its community highlights its unique, permissionless brand-building approach and consistent IRL product initiatives, fostering high engagement and long-term conviction among holders. Investors are actively discussing the project's resilience and expansion efforts, often positioning it as a standout, long-term opportunity within the broader crypto market.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing intense community debate as investors weigh the highly anticipated Goliath mainnet launch against a history of volatile price action and skeptical sentiment regarding long-term utility. While bulls focus on infrastructure developments and staking rewards, bears are actively highlighting recurring patterns of rapid price spikes followed by significant pullbacks.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as shares surged following positive topline Phase 3 results for its drug Zenkuda, which successfully met primary and secondary endpoints in treating diabetic retinopathy. The community is actively discussing the stock's significant price volatility, debating the potential for a short squeeze given the high short interest, and weighing the company's long-term prospects as it moves from clinical trials toward a potential BLA submission.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending due to a mix of volatile price action following a recent $350 million equity offering and intense debate over its Phase 1 obesity trial data. While some community members argue the trial design was flawed and overvalued compared to competitors, others see the visceral fat reduction and muscle preservation as best-in-class results, leading to strong analyst support and ongoing speculation regarding potential M&A activity.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending following speculative buyout rumors linked to Eli Lilly and significant volume spikes that have ignited community debate over potential valuation and long-term M&A prospects. Investors are closely monitoring its market leadership in the MASH space as the company navigates competition and expands its pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global stock market chart and trading board - stock photo

Evaxion Appoints Helen Tayton-Martin As Chief Executive

Tayton-Martin will take over as the CEO on November 24, the company said.

Equity

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Evaxion A/S (EVAX) said on Thursday that it has out-licensed its vaccine candidate EVX-B3 to Merck (MRK), sending shares of the company rallying 42% in the pre-market session.Evaxion will receive a cash payment of $7.5 million in addition to future milestone payments of up to $592 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://evaxion.ai/investors/press-releases/?press_release_id=10586">said</a>. It will also be eligible for royalties on net sales.The cash payment will extend Evaxion’s cash runway to the first half of 2027, it said. Cash at hand will be invested in operating and developing the business, it added.The out-licensing is part of the option and license agreement between the two companies in September 2024. Merck will now be wholly responsible for the further development of the EVX-B3 vaccine, which is in preclinical development.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EVAX">EVAX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.EVX-B3 was discovered and developed in a collaboration between Evaxion and Merck. It aims to address a serious global medical issue for which no vaccines are currently available, Evaxion said, without naming the condition.Merck retains an option in a second vaccine candidate called EVX-B2. It is a preclinical vaccine candidate against Gonorrhea, and a decision on potential licensing is expected in the first half of 2026. Were Merck to exercise the option, Evaxion will receive a cash payment of $2.5 million and will be eligible for milestone payments of up $592 million in addition to royalties on sales.EVAX stock is down 22% this year and approximately 77% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Evaxion A/S - ADR

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

EVAX
Evaxion Biotech

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EVAX News

EVAXEvaxion Biotech